NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights. “With multiple clinical-stage programs aimed at addressing significant unmet patient needs…


Previous articlePsyence Group Announces Cantheon Capital Private Placement
Next articlePsychedelics Weekly – More Trouble For Field Trip Health, Ketamine Wellness Centers Abruptly Close, & The Creation of the Psychedelic Medicine PAC